ArcherDX v. Qiagen: Cross-Appeal Dismissed in Genomic Sequencing Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | ArcherDX, LLC, et al. v. Qiagen Sciences LLC, et al. |
| Case Number | 2023-2379 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from D.C. |
| Duration | Sept 12, 2023 – Mar 27, 2024 6 months |
| Outcome | Procedural Dismissal — Joint Stipulation |
| Patents at Issue | |
| Accused Products | Nucleic Acid Sequencing Methods/Products |
Case Overview
The Parties
In a procedurally notable conclusion to one branch of a complex genomic sequencing patent dispute, the U.S. Court of Appeals for the Federal Circuit dismissed Appeal No. 2023-2379 on March 27, 2024, following a joint stipulation by both parties. The case pitted ArcherDX, LLC and The General Hospital Corporation against a constellation of Qiagen entities over two U.S. patents covering nucleic acid sequencing methods — technologies sitting at the intersection of precision medicine and next-generation genomic diagnostics.
⚖️ Plaintiffs
ArcherDX is a molecular diagnostics company specializing in targeted genomic sequencing solutions. The General Hospital Corporation co-holds foundational patents in nucleic acid research methodologies.
🛡️ Defendants
Qiagen is a multinational life sciences company offering sample preparation and assay technologies. This case involved six distinct Qiagen corporate entities and an individual defendant.
Patents at Issue
This dispute centered on two U.S. patents covering nucleic acid sequencing methods, crucial for targeted sequencing and library preparation protocols. Both patents protect upstream enabling methodologies in next-generation sequencing (NGS).
- • U.S. Patent No. 10,017,810 B2 — Methods for determining a nucleotide sequence contiguous to a known target nucleotide sequence.
- • U.S. Patent No. 10,450,597 B2 — Methods of preparing nucleic acids for sequencing.
Developing a new genomic sequencing product?
Check if your nucleic acid sequencing methods might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
Appeal No. 2023-2379 was dismissed by joint stipulation pursuant to Federal Rule of Appellate Procedure 42(b), with each party bearing its own costs. No damages award, claim construction ruling, or merits determination was issued in connection with this specific appeal. The dismissal was unopposed and procedurally clean, indicating mutual agreement to narrow the appellate proceedings rather than litigate this particular cross-appeal to judgment.
Key Legal Issues
The decision to jointly stipulate dismissal — rather than brief and argue the cross-appeal — may reflect strategic considerations such as cost-benefit analysis or issue narrowing. Critically, a companion appeal — No. 2023-2350 — remained active, signaling that the broader patent infringement dispute between these parties was far from resolved at the time of this dismissal. The procedural split between the two appeals suggests strategic maneuvering by both sides, potentially narrowing the issues before the merits panel or realigning litigation costs ahead of a more consequential ruling.
Freedom to Operate (FTO) Analysis in Genomic Sequencing
This case highlights critical IP risks in nucleic acid sequencing. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in the genomic sequencing space
- See which companies are most active in NGS patents
- Understand claim construction patterns for method patents
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own genomic sequencing technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Upstream sequencing preparation methods
2 Patents at Issue
In this specific litigation
Design-Around Options
Available for specific claims
✅ Key Takeaways
Joint stipulations under FRAP 42(b) are powerful procedural tools for appellate issue narrowing — but must be weighed against potential waiver risks.
Search related case law →Multi-entity defendant structures require coordinated legal strategy from initial case assessment through appeal.
Explore litigation strategies →Frequently Asked Questions
The dispute centered on U.S. Patent No. 10,017,810 B2 and U.S. Patent No. 10,450,597 B2, both covering methods in nucleic acid sequencing preparation and target sequence determination.
Both parties jointly stipulated to dismiss the cross-appeal under Federal Rule of Appellate Procedure 42(b), with each side bearing its own costs. No merits ruling was issued.
No. Companion Appeal No. 2023-2350 remained active before the Federal Circuit, with Qiagen’s reply brief due April 15, 2024, meaning the core infringement and validity questions were still pending.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- U.S. Court of Appeals for the Federal Circuit
- USPTO Patent Center
- PACER (Public Access to Court Electronic Records)
- Google Scholar – ArcherDX v. Qiagen
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.